Nuvalent (NUVL) Total Current Liabilities (2020 - 2026)
Nuvalent's (NUVL) quarterly Total Current Liabilities came in at $81.1 million in Q1 2026, up 8.02% YoY from $75.0 million in Q1 2025, and down 11.1% on a QoQ basis from $91.2 million in Q4 2025.
Nuvalent (NUVL) Total Current Liabilities (2020 - 2026) Analysis & Trends
Nuvalent (NUVL) has 7 years of Total Current Liabilities data on file, last reported at $81.1 million in Q1 2026.
- Quarterly Total Current Liabilities rose 8.02% year-over-year to $81.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $81.1 million (up 8.02% YoY) and the FY2025 annual result came in at $91.2 million, up 68.77% from the prior year.
- Total Current Liabilities fell to $81.1 million in Q1 2026, from $91.2 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $91.2 million in Q4 2025 to a low of $8.1 million in Q1 2022.
- A 5-year average of $43.4 million and a median of $33.4 million in 2024 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2025 — Total Current Liabilities surged 124.47% — and 2026, when it increased 8.02%.
- Tracing NUVL's Total Current Liabilities over 5 years: stood at $19.5 million in 2022, then surged by 63.35% to $31.8 million in 2023, then jumped by 69.75% to $54.0 million in 2024, then surged by 68.77% to $91.2 million in 2025, then decreased by 11.1% to $81.1 million in 2026.
- The last three Total Current Liabilities figures came in at $81.1 million (Q1 2026), $91.2 million (Q4 2025), and $89.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Nuvalent | 9.10 Bn | 9.10 Bn | - | 81.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 81.05 Mn |
| Dec 31, 2025 | 91.17 Mn |
| Sep 30, 2025 | 89.15 Mn |
| Jun 30, 2025 | 75.15 Mn |
| Mar 31, 2025 | 75.03 Mn |
| Dec 31, 2024 | 54.02 Mn |
| Sep 30, 2024 | 51.13 Mn |
| Jun 30, 2024 | 38.19 Mn |
| Mar 31, 2024 | 33.43 Mn |
| Dec 31, 2023 | 31.82 Mn |
| Sep 30, 2023 | 29.10 Mn |
| Jun 30, 2023 | 20.80 Mn |
| Mar 31, 2023 | 17.02 Mn |
| Dec 31, 2022 | 19.48 Mn |
| Sep 30, 2022 | 12.98 Mn |
| Jun 30, 2022 | 10.04 Mn |
| Mar 31, 2022 | 8.12 Mn |
| Dec 31, 2021 | 8.79 Mn |
| Sep 30, 2021 | 6.84 Mn |
| Jun 30, 2021 | 5.83 Mn |